<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141589">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257737</url>
  </required_header>
  <id_info>
    <org_study_id>HPN-100-011</org_study_id>
    <nct_id>NCT01257737</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)</brief_title>
  <official_title>Long Term Use of HPN-100 in Urea Cycle Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma Ireland, Ltd., Dublin Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present protocol is a treatment protocol to allow continued use of HPN-100 for the
      treatment of UCD subjects who complete 12 months of treatment in Study HPN-100-005,
      (NCT00947544), HPN-100-007, (NCT00947297), or HPN-100-012, (NCT01347073). Under this
      protocol, long-term safety will continue to be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present protocol will allow subjects continued use of HPN-100 following their treatment
      and study completion in Study HPN-100-005, HPN-100-007, or HPN-100-012. Subjects will be
      able to continue in this study until approval and commercial availability of HPN-100 in each
      country participating in this study. Subjects will be required to return to the clinic every
      6 months in which physical exam, safety labs, dietary assessment and neuropsychological
      testing will occur. Subjects will be dispensed sufficient HPN-100 to last until the next
      clinic visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 16, 2017</completion_date>
  <primary_completion_date type="Actual">February 16, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>Every six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Venous ammonia levels</measure>
    <time_frame>Every six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyperammonemic crises</measure>
    <time_frame>Every six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological testing</measure>
    <time_frame>Every twelve months</time_frame>
    <description>Wechsler Abbreviated Scale of Intelligence (WASI) The California Verbal Learning Test (CVLT) Digit Span The Child Behavior Checklist (CBCL) Behavior Rating Inventory of Executive Function® (BRIEF®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causes of hyperammonemic crises</measure>
    <time_frame>Every six month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Urea Cycle Disorders</condition>
  <arm_group>
    <arm_group_label>HPN-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will continue treatment with HPN-100 after having completed HPN-100 treatment in HPN-100-005, HPN-100-007, or HPN-100-012.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPN-100</intervention_name>
    <description>HPN-100 will be administered orally three times daily (TID) with meals. The maximum recommended dose of HPN-100 in subjects weighing less than 20 kg is 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and is 11.48 mL/m2/day in heavier subjects (equivalent to 13g/m2/day of NaPBA). The maximum HPN-100 dose should be 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.</description>
    <arm_group_label>HPN-100</arm_group_label>
    <other_name>GT4P, Glyceryl tri-(4-phenylbutyrate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects who completed HPN-100-005,(NCT00947544),
             HPN-100-007,(NCT00947297), or HPN-100-012,(NCT01347073).

          -  Signed informed consent by subject and/or subject's legally authorized
             representative.

          -  Negative pregnancy test for all females of childbearing potential.

        Exclusion Criteria:

          -  Any clinical or laboratory abnormality or medical condition that, at the discretion
             of the investigator, may put the subject at increased risk when participating.

          -  Known hypersensitivity to PAA,(phenylacetate) or PBA,(phenylbutyrate).

          -  Liver transplant, including hepatocellular transplant.

          -  Pregnant, breastfeeding or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen Canavan, BS</last_name>
    <role>Study Chair</role>
    <affiliation>Horizon Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Pediatrics/Genetics</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburg of UPMC</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 24, 2017</lastchanged_date>
  <firstreceived_date>December 2, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urea Cycle Disorders</keyword>
  <keyword>GT4P</keyword>
  <keyword>HPN-100</keyword>
  <keyword>Sodium Phenylbutyrate</keyword>
  <keyword>Glyceryl tri-(4-phenylbutyrate)</keyword>
  <keyword>Phenylbutyrate</keyword>
  <keyword>Hyperion</keyword>
  <keyword>Buphenyl</keyword>
  <keyword>hyperammonemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
